EAP for AI tech to detect haemorrhageJanuary 14, 2019
A software medical device for intracranial haemorrhage detection has been granted the Expedited Access Pathway (EAP) designation by the USFDA.
The device, based on deep learning technologies, automatically analyses noncontrast head CT images. It is designed to be highly sensitive to the presence of intracranial haemorrhage (ICH) in these scans and to alert the treating physician when ICH is detected.
Noncontrast head CT is the standard for initial assessment of potential ICH in emergency medicine settings.
MedyMatch has developed a broad machine vision and deep learning platform to support the assessment of multiple clinical indications.
The EAP programme is designed to facilitate rapid patient access to medical devices that demonstrate the potential to address unmet medical needs for life-threatening or irreversibly debilitating diseases or conditions.\
Based in Tel Aviv, Israel, MedyMatch is a medical AI company delivering a clinical decision support platform to improve patient outcomes in acute medical scenarios.